Pharmagen Stock Net Income
| PHRX Stock | USD 0.0001 0.00 0.00% |
Pharmagen fundamentals help investors to digest information that contributes to Pharmagen's financial success or failures. It also enables traders to predict the movement of Pharmagen Stock. The fundamental analysis module provides a way to measure Pharmagen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmagen stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -5.4 M | -5.1 M | |
| Net Loss | -5.8 M | -5.5 M | |
| Net Loss | -5.4 M | -5.1 M | |
| Net Loss | (0.02) | (0.02) | |
| Net Income Per E B T | 0.97 | 0.86 |
Pharmagen | Net Income |
Pharmagen Company Net Income Analysis
Pharmagen's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pharmagen Net Income | (6 M) |
Most of Pharmagen's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmagen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pharmagen Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pharmagen is extremely important. It helps to project a fair market value of Pharmagen Stock properly, considering its historical fundamentals such as Net Income. Since Pharmagen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pharmagen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pharmagen's interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Pharmagen reported net income of (6 Million). This is 101.76% lower than that of the Health Care Providers & Services sector and 102.93% lower than that of the Health Care industry. The net income for all United States stocks is 101.05% higher than that of the company.
Pharmagen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmagen's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmagen could also be used in its relative valuation, which is a method of valuing Pharmagen by comparing valuation metrics of similar companies.Pharmagen is currently under evaluation in net income category among its peers.
Pharmagen Fundamentals
| Return On Asset | -0.59 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 5.93 M | ||||
| Shares Outstanding | 517.08 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.08 X | ||||
| Revenue | 4.81 M | ||||
| Gross Profit | 3.05 M | ||||
| EBITDA | (2.13 M) | ||||
| Net Income | (6 M) | ||||
| Cash And Equivalents | 264.67 K | ||||
| Total Debt | 2.16 M | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (692.07 K) | ||||
| Target Price | 0.13 | ||||
| Number Of Employees | 24 | ||||
| Beta | -0.065 | ||||
| Market Capitalization | 361.95 K | ||||
| Total Asset | 1.28 M | ||||
| Working Capital | (7.46 M) | ||||
| Current Asset | 837 K | ||||
| Current Liabilities | 8.29 M | ||||
| Net Asset | 1.28 M |
About Pharmagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmagen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmagen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.